Cargando…

Matrix metalloproteinase-2 is elevated in midtrimester amniotic fluid prior to the development of preeclampsia

OBJECTIVE: To evaluate levels of matrix metalloproteinases (MMP) and their inhibitors (TIMP) in second trimester amniotic fluid of women with hypertensive disorders compared to normotensive women. STUDY DESIGN: Amniotic fluid was obtained from 133 women undergoing genetic second trimester amniocente...

Descripción completa

Detalles Bibliográficos
Autores principales: Lavee, Michal, Goldman, Shlomit, Daniel-Spiegel, Etty, Shalev, Eliezer
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2733305/
https://www.ncbi.nlm.nih.gov/pubmed/19698156
http://dx.doi.org/10.1186/1477-7827-7-85
_version_ 1782171101690855424
author Lavee, Michal
Goldman, Shlomit
Daniel-Spiegel, Etty
Shalev, Eliezer
author_facet Lavee, Michal
Goldman, Shlomit
Daniel-Spiegel, Etty
Shalev, Eliezer
author_sort Lavee, Michal
collection PubMed
description OBJECTIVE: To evaluate levels of matrix metalloproteinases (MMP) and their inhibitors (TIMP) in second trimester amniotic fluid of women with hypertensive disorders compared to normotensive women. STUDY DESIGN: Amniotic fluid was obtained from 133 women undergoing genetic second trimester amniocentesis. Zymography was performed for MMP characterization and an MMP-2 ELISA kit was used to determine MMP-2 levels. TIMP-2 expression was evaluated using western blot. RESULTS: Mean amniotic fluid MMP-2 and TIMP-2 levels were significantly higher in women who developed a hypertensive disorder compared to normotensive women (P < 0.0004 and P < 0.01, respectively). When subdivided into subgroups, amniotic fluid from women who eventually developed preeclampsia or superimposed preeclampsia showed significantly higher MMP-2 levels than normotensive women (P < 0.05). However, no statistical difference in MMP-2 levels was found between patients with gestational hypertension and normotensive patients. CONCLUSION: Higher amniotic fluid MMP-2 and TIMP-2 levels are found in women who eventually develop preeclampsia.
format Text
id pubmed-2733305
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27333052009-08-28 Matrix metalloproteinase-2 is elevated in midtrimester amniotic fluid prior to the development of preeclampsia Lavee, Michal Goldman, Shlomit Daniel-Spiegel, Etty Shalev, Eliezer Reprod Biol Endocrinol Research OBJECTIVE: To evaluate levels of matrix metalloproteinases (MMP) and their inhibitors (TIMP) in second trimester amniotic fluid of women with hypertensive disorders compared to normotensive women. STUDY DESIGN: Amniotic fluid was obtained from 133 women undergoing genetic second trimester amniocentesis. Zymography was performed for MMP characterization and an MMP-2 ELISA kit was used to determine MMP-2 levels. TIMP-2 expression was evaluated using western blot. RESULTS: Mean amniotic fluid MMP-2 and TIMP-2 levels were significantly higher in women who developed a hypertensive disorder compared to normotensive women (P < 0.0004 and P < 0.01, respectively). When subdivided into subgroups, amniotic fluid from women who eventually developed preeclampsia or superimposed preeclampsia showed significantly higher MMP-2 levels than normotensive women (P < 0.05). However, no statistical difference in MMP-2 levels was found between patients with gestational hypertension and normotensive patients. CONCLUSION: Higher amniotic fluid MMP-2 and TIMP-2 levels are found in women who eventually develop preeclampsia. BioMed Central 2009-08-23 /pmc/articles/PMC2733305/ /pubmed/19698156 http://dx.doi.org/10.1186/1477-7827-7-85 Text en Copyright © 2009 Lavee et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Lavee, Michal
Goldman, Shlomit
Daniel-Spiegel, Etty
Shalev, Eliezer
Matrix metalloproteinase-2 is elevated in midtrimester amniotic fluid prior to the development of preeclampsia
title Matrix metalloproteinase-2 is elevated in midtrimester amniotic fluid prior to the development of preeclampsia
title_full Matrix metalloproteinase-2 is elevated in midtrimester amniotic fluid prior to the development of preeclampsia
title_fullStr Matrix metalloproteinase-2 is elevated in midtrimester amniotic fluid prior to the development of preeclampsia
title_full_unstemmed Matrix metalloproteinase-2 is elevated in midtrimester amniotic fluid prior to the development of preeclampsia
title_short Matrix metalloproteinase-2 is elevated in midtrimester amniotic fluid prior to the development of preeclampsia
title_sort matrix metalloproteinase-2 is elevated in midtrimester amniotic fluid prior to the development of preeclampsia
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2733305/
https://www.ncbi.nlm.nih.gov/pubmed/19698156
http://dx.doi.org/10.1186/1477-7827-7-85
work_keys_str_mv AT laveemichal matrixmetalloproteinase2iselevatedinmidtrimesteramnioticfluidpriortothedevelopmentofpreeclampsia
AT goldmanshlomit matrixmetalloproteinase2iselevatedinmidtrimesteramnioticfluidpriortothedevelopmentofpreeclampsia
AT danielspiegeletty matrixmetalloproteinase2iselevatedinmidtrimesteramnioticfluidpriortothedevelopmentofpreeclampsia
AT shaleveliezer matrixmetalloproteinase2iselevatedinmidtrimesteramnioticfluidpriortothedevelopmentofpreeclampsia